StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.
Oragenics Trading Up 2.8 %
Shares of OGEN stock opened at $1.09 on Wednesday. Oragenics has a twelve month low of $1.02 and a twelve month high of $7.74. The company has a market cap of $4.88 million, a P/E ratio of -0.12 and a beta of 0.31. The stock’s fifty day simple moving average is $1.88.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings data on Friday, March 29th. The company reported ($5.48) earnings per share for the quarter.
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Featured Articles
- Five stocks we like better than Oragenics
- Breakout Stocks: What They Are and How to Identify Them
- Charles Schwab Fortifies its Uptrend on EPS Beat
- The How and Why of Investing in Gold Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What is the Dow Jones Industrial Average (DJIA)?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
